Evaluating Key Clinical Updates in the Realm of Endometrial Cancer | Supplements and Featured Publications

November 04, 2024

David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.

October 25, 2024

David S. Miller, MD, discusses the efficacy of selinexor in patients with advanced or recurrent TP53 wild-type endometrial cancer.

January 03, 2024

Debra L. Richardson, MD, FACS, FACOG, discusses the impact of selinexor’s mechanism of action on the agent’s clinical efficacy in patients with TP53 wild-type advanced or recurrent endometrial cancer.

November 22, 2023

Maintenance therapy with selinexor improved progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer, regardless of microsatellite instability status.

November 09, 2023

Brian M. Slomovitz, MD, discusses the phase 3 DUO-E and AtTEnd trials investigating the use immunotherapy in endometrial cancer, as presented at the 2023 ESMO Congress.

October 27, 2023

Mansoor Raza Mirza, MD, discusses treatment outcomes with the use of dostarlimab plus chemotherapy in patients with primary advanced or recurrent endometrial cancer whose disease was mismatch repair deficient/microsatellite instability–high, TP53 mutated, or had no specific molecular profile.

October 23, 2023

Patients with primary advanced or recurrent endometrial cancer whose disease was deficient mismatch repair/microsatellite instability-high, TP53 mutated, or had no specific molecular profile, experienced a survival benefit when treated with dostarlimab-gxly plus chemotherapy vs placebo plus chemotherapy.

October 21, 2023

Shannon N. Westin, MD, MPH, FACOG, discusses key data on the use of durvalumab plus chemotherapy followed by durvalumab and olaparib maintenance in the phase 3 DUO-E trial of patients with newly diagnosed advanced or recurrent endometrial cancer.